UDK: 615.224:542.542.978

INHIBITORS OF ANGIOTENSIN-II AT 1 RECEPTOR C-TERMINAL FRAGMENT AS A NEW CLASS OF CARDIOVASCULAR DRUGS

N. G. Chepurina

Кафедра клинической фармакологии и интенсивной терапии ВолГМУ

Abstract

The drug development of anti-endogenic-regulator antibodies is a perspective modern pharmacology direction. Cardos as ultralow dose of antibodies to angiotensin-II AT1 receptor C-terminal fragment modulates the receptor functional activity. Experimental investigations have shown mild antihypertensive activity of cardos which increases the physical exercise tolerance as well. Pilot clinical investigation results of the Cardos treatment have confirmed experimental data.

Keywords

ultralow doses of antibodies, angiotensin-II-type-1-receptor antibodies, Cardos, arterial hypertension, chronic heart failure

Contacts

Чепурина Наталья Геннадьевна – к.м.н., докторант кафедры кафедры клинической фармакологии и интенсивной терапии с курсами клинической фармакологии ФУВ, клинической аллергологии ФУВ, восстановительной терапии и курортологии ФУВ ВолГМУ